QPPV.COM KNOWLEDGE ASSESSMENT

Serplulimab: Classification, Mechanism, Evidence and Pharmacovigilance

Test your understanding of the concepts covered by Serplulimab: Classification, Mechanism, Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best distinguishes class pharmacology from indication-specific clinical evidence?
Question 2 of 10 Which statement best reflects the relationship between serplulimab and chemotherapy in the current EU scope described by the article?
Question 3 of 10 A patient develops inflammation in a previously unaffected organ after treatment has been stopped. Which interpretation is most consistent with the article?
Question 4 of 10 Which statement best characterises hypothyroidism in the article's safety discussion?
Question 5 of 10 A company announcement describes a new serplulimab use, but the current EMA product information has not been checked. What should an EU regulatory professional do before treating that use as authorised?
Question 6 of 10 In ASTRUM-005, the hazard ratio for death was 0.63 for serplulimab plus chemotherapy versus placebo plus chemotherapy. Which interpretation is most appropriate?
Question 7 of 10 An event arises several months after treatment begins. What does the article indicate about using latency in the causality assessment?
Question 8 of 10 Which practice best supports signal detection for suspected immune-mediated events?
Question 9 of 10 A patient on serplulimab develops cough, hypoxia, and new pulmonary opacities. Which differential diagnosis is specifically important to consider?
Question 10 of 10 A team is considering applying the overall-survival estimate from ASTRUM-005 to a patient receiving serplulimab for NSCLC. What is the most appropriate interpretation?

Select an answer to continue.

QPPV.com